3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
11
Colorectal Neoplasms
10
Neoplasm Metastasis
6
Rhabdomyosarcoma
3
Neuroblastoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Sarcoma
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Solid Tumors
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Refractory Solid Tumors
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Medulloblastoma
1
Malignant mesenchymal tumor
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Irinotecan
×
30 days
×
Clear all
No trials found.